Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Sponsor
Xiayun He, MD
Study ID
NCT03300765
Phase
PHASE2
Status
Unknown

Conditions

  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib will be used as induction therapy in experimental arm.
  • Intensity modulated radiation therapy — RADIATION
    Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.

Study Details

To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.

Key Dates

Start date
Jul 1, 2017
Status verified
Sep 2017
Primary completion
Jul 1, 2019
Completion
May 1, 2020

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib with IMRT
    Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)

Primary Outcome Measure

Progression Free Survival [ Time Frame: 3-year ]

Central Contacts

Related Studies